The objective of the present study is to develop sustained release of dipyridamole, a poorly
soluble weakly basic compound. The solubility of dipyridamole is the limit step of its …

This study was undertaken to develop new dipyridamole (DP) formulations with acidic
microenvironmental pH-modifiers for improving dissolution and absorption under …

The present study aimed to develop and characterize new formulations of dipyridamole
(DP), a pH-dependent poorly soluble drug, employing an acidic pH-modifier for improving …

Incorporation of weak acids as pH modifiers enhances the release of weakly basic drugs in
higher pH environments by reducing the microenvironmental pH (pHM). The objectives of …

The aim of this study was to develop a pH-independent release formulation of dipyridamole
(DP) by the combined use of pH-modifier technology and solid dispersion (SD) technology …

ABSTRACT Introduction: Dipyridamole is an Anti-platelet agent exhibits release problems at
higher pH of small intestine due to its pH dependent solubility and precipitation followed by …

Dipyridamole shows poor and variable bioavailability after oral administration due to
pHdependent solubility, low biomembrane permeability as well as being a substrate of P …

The aim of this research was to design and evaluate a hydrophilic matrix system for
sustained release of glipizide, a weakly acidic poor soluble drug. A combination of inclusion …

Tailor-made, pH-controlled matrix minitablets based on different HPMC types were
developed comprising the weakly basic drug dipyridamole. The incorporation of pH …

Aim: The present investigation concerns the development of controlled release matrix tablet
of Diltiazem HCl. Methods: Matrix tablet of Diltiazem HCl was formulated by using HPMC …